We focus on the treatment of chronic low back pain caused by the degeneration of intervertebral discs.
Our patented polymer gel helps to restore the natural integrity of the disc itself. Injected directly, it rehydrates
and stabilises, allowing cells to work normally, bringing back load bearing properties, and restoring the movement of the patient.
Gelmetix’s DXM is not a drug. It is a biological solution that intervenes at the early phase of degenerative disc disease. It restores water content and helps cells to return to their normal function. It provides a minimally invasive alternative to surgery or pain management and improvement in quality of life.
Gelmetix’s DXM tackles the source of chronic low-back pain by helping to restore the disc itself and relieve pain1,2. Injected under local anaesthetic, directly into the disc, which means an ambulant procedure. DXM is an investigational product and not yet publicly available.
Gelmetix’s patented polymer technology provides a platform for tackling pain and restoring movement for chronic low-back pain, and in joints throughout the body. Our gels also offer the potential to act as a carrier, allowing the introduction of regenerative agents. This flexibility creates great potential for Gelmetix to offer an extendable technology platform.
1Gelmetix data on file (preclinical) 2An injectable nucleus replacement as an adjunct to microdiscectomy: 2 year follow-up in a pilot clinical study. Berlemann U, Schwarzenbach O. Eur Spine J. 2009;18:1706–1712.